FY2025 Earnings Estimate for MNMD Issued By Chardan Capital

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) – Chardan Capital issued their FY2025 earnings estimates for shares of Mind Medicine (MindMed) in a research note issued on Monday, March 24th. Chardan Capital analyst R. Li anticipates that the company will post earnings of ($1.70) per share for the year. Chardan Capital currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Mind Medicine (MindMed)’s current full-year earnings is ($1.35) per share.

MNMD has been the subject of several other reports. HC Wainwright reiterated a “buy” rating and set a $55.00 target price on shares of Mind Medicine (MindMed) in a research report on Friday, March 7th. Evercore ISI assumed coverage on shares of Mind Medicine (MindMed) in a report on Tuesday, January 28th. They set an “outperform” rating and a $23.00 price objective for the company. Oppenheimer reissued an “outperform” rating and issued a $20.00 target price on shares of Mind Medicine (MindMed) in a research note on Tuesday, December 17th. Finally, Robert W. Baird dropped their price target on Mind Medicine (MindMed) from $27.00 to $16.00 and set an “outperform” rating for the company in a research note on Friday, March 7th. Ten equities research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat, Mind Medicine (MindMed) currently has an average rating of “Buy” and an average target price of $25.11.

Mind Medicine (MindMed) Stock Down 2.3 %

Shares of NASDAQ MNMD opened at $6.43 on Thursday. The company has a current ratio of 9.00, a quick ratio of 9.00 and a debt-to-equity ratio of 0.09. The business has a 50-day moving average of $7.28 and a 200-day moving average of $6.95. The firm has a market capitalization of $484.62 million, a price-to-earnings ratio of -2.85 and a beta of 2.57. Mind Medicine has a 12 month low of $5.03 and a 12 month high of $12.22.

Mind Medicine (MindMed) (NASDAQ:MNMD) last posted its earnings results on Thursday, March 6th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.08). During the same period last year, the firm posted ($0.59) earnings per share.

Institutional Trading of Mind Medicine (MindMed)

Several institutional investors and hedge funds have recently bought and sold shares of MNMD. Barclays PLC raised its position in shares of Mind Medicine (MindMed) by 203.6% in the 3rd quarter. Barclays PLC now owns 136,098 shares of the company’s stock worth $775,000 after acquiring an additional 91,271 shares in the last quarter. Wellington Management Group LLP lifted its position in Mind Medicine (MindMed) by 142.6% during the third quarter. Wellington Management Group LLP now owns 185,722 shares of the company’s stock valued at $1,057,000 after buying an additional 109,152 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Mind Medicine (MindMed) by 10.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,677,702 shares of the company’s stock valued at $9,548,000 after buying an additional 162,933 shares in the last quarter. SG Americas Securities LLC grew its position in shares of Mind Medicine (MindMed) by 48.8% in the 4th quarter. SG Americas Securities LLC now owns 24,406 shares of the company’s stock worth $170,000 after buying an additional 8,004 shares during the period. Finally, State Street Corp increased its stake in shares of Mind Medicine (MindMed) by 0.5% in the 3rd quarter. State Street Corp now owns 1,814,829 shares of the company’s stock worth $10,326,000 after acquiring an additional 9,782 shares in the last quarter. 27.91% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Mind Medicine (MindMed)

In other news, CEO Robert Barrow sold 21,208 shares of the firm’s stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $6.74, for a total value of $142,941.92. Following the completion of the sale, the chief executive officer now directly owns 856,556 shares of the company’s stock, valued at approximately $5,773,187.44. This trade represents a 2.42 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Daniel Karlin sold 6,836 shares of the business’s stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $6.74, for a total transaction of $46,074.64. Following the transaction, the insider now owns 446,177 shares in the company, valued at $3,007,232.98. This represents a 1.51 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 30,391 shares of company stock worth $204,835. Insiders own 2.26% of the company’s stock.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.